Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Novo receives second CRL for rFXIII, reports 1H13 financials

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) disclosed in its 1H13 earnings on Thursday that it received in June a second complete response letter from FDA for a BLA for recombinant factor XIII ( rFXIII) to treat congenital Factor XIII deficiency,

Read the full 392 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE